The Glucagon Receptor Is Involved in Mediating the Body Weight‐Lowering Effects of Oxyntomodulin
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Oxyntomodulin (OXM) is a peptide secreted postprandially from the L‐cells of the gut that has a weak affinity for both the glucagon‐like peptide‐1 receptor (GLP1R) and the glucagon receptor (GCGR). Peripheral administration of OXM in humans and rodents causes weight loss reducing food intake and increasing energy expenditure. It has been suggested that OXM modulates energy intake solely through GLP1R agonism. Because glucagon decreases food intake in rodents and humans, we examined whether activation of the GCGR is involved in the body weight‐lowering effects of OXM. We identified an equipotent GLP1R‐selective peptide agonist that differs from OXM by only one residue (Q3→E, OXMQ3E), but has no significant GCGR agonist activity in vitro and ∼100‐fold reduced ability to stimulate liver glycogenolysis. Chronic treatment of obese mice with OXM and OXMQ3E demonstrated that OXM exhibits superior weight loss and lipid‐lowering efficacy, and antihyperglycemic activity that is comparable to the corresponding GLP1R‐selective agonist. Studies in Glp1r−/− mice and coadministration of OXM and a GCGR antagonist revealed that the antiobesity effect of OXM requires activation of both GLP1R and GCGR. Our data provide new insight into the mechanism of action of OXM and suggest that activation of GCGR is involved in the body weight‐lowering action of OXM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · cited 4×
“Glucagon-like peptide-1-(7-36) amide, oxyntomodulin, and glucagon interact with a common receptor in a somatostatin-secreting cell line.”
BackgroundMethodInfluentialSubcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects
Wynne, K., Park, A. J., Small, C. J., Patterson, M., Ellis, S. M., Murphy, K. G., Wren, A. M., Frost, G. S., Meeran, K., Ghatei, M. A., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2390 · Cited by 435 · cited 2×
“Although OXM inhibits food intake in rodents (2,3) as well as in human subjects (1), the precise receptors and signaling pathways mediating the anorectic action of OXM remain uncertain.”
BackgroundBaggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.063 · Cited by 372
Wynne, K., Park, A. J., Small, C. J., Meeran, K., Ghatei, M. A., Frost, G. S., & Bloom, S. R. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803344 · Cited by 363
Metabolic effects of glucagon in the Wistar rat
SALTER, J. M. (1960) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/8.5.535 · Cited by 85 · cited 2×
“Glucagon-like peptide-1-(7-36) amide, oxyntomodulin, and glucagon interact with a common receptor in a somatostatin-secreting cell line.”
Background
Cited by
Furness, J. B., Rivera, L. R., Cho, H.-J., Bravo, D. M., & Callaghan, B. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.180 · Cited by 526
The New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419
“Peripheral administration of OXM but not OXMQ3E induced weight loss in GLP-1R KO mice, thus indicating that the body weight-lowering effect of OXM may be achieved through GLP-1R and GcGR signaling (364).”
BackgroundGlucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
Baggio, L. L., & Drucker, D. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101090 · Cited by 299
“Indeed, a combination of peptide mutagenesis to eliminate the glucagon activity from oxyntomodulin, combined with studies in Glp1r / mice or WT mice using a GCGR antagonist, have highlighted the importance of both the GCGR and GLP-1R for the maximal weight loss effect ensuing from oxyntomodulin administration [43].”
BackgroundAnti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
Action and therapeutic potential of oxyntomodulin
Pocai, A. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2013.12.001 · Cited by 191
Self-citation
Metadata
- Authors
- Kosinski, J. R., Hubert, J., Carrington, P. E., Chicchi, G. G., Mu, J., Miller, C., Cao, J., Bianchi, E., Pessi, A., SinhaRoy, R., Marsh, D. J., & Pocai, A.
- Venue
- Obesity
- Publisher
- Wiley
- Published
- 2012-08
- Volume
- 20
- Issue
- 8
- Pages
- 1566-1571
- ISSN
- 1930-7381 (ISSN-L)
- 1930-739X
- OpenAlex
- W2026149528
- Cited by
- 106
- References
- 6
- FWCI
- 3.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Glucagon Receptor Is Involved in Mediating the Body Weight‐Lowering Effects of Oxyntomodulin. https://app.cochat.ai/papers/10.1038/oby.2012.67
- The paper
- Kosinski, J. R., Hubert, J., Carrington, P. E., Chicchi, G. G., Mu, J., Miller, C., Cao, J., Bianchi, E., Pessi, A., SinhaRoy, R., Marsh, D. J., & Pocai, A. (2012). The Glucagon Receptor Is Involved in Mediating the Body Weight‐Lowering Effects of Oxyntomodulin. Obesity. https://doi.org/10.1038/oby.2012.67
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.